Quick Answer
Immunocore Holdings plc reported Cash and Equivalents of $467.71 million for fiscal year 2025.
Immunocore Holdings plc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $467.71M | +2.6% |
| 2024 | $455.73M | +3.0% |
| 2023 | $442.63M | +10.0% |
| 2022 | $402.47M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $498.41M | -7.3% | +2.1% |
| June 30, 2025 | $487.93M | -3.4% | +2.3% |
| March 31, 2025 | $476.85M | -42.7% | +4.6% |
| December 31, 2024 | $455.73M | +3.0% | -15.3% |
| September 30, 2024 | $537.77M | — | +6.5% |
| June 30, 2024 | $504.99M | — | -39.4% |
| March 31, 2024 | $832.82M | — | +88.2% |
| December 31, 2023 | $442.63M | — | — |
- Immunocore Holdings plc showed an increase of +2.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, Immunocore Holdings plc’s cash and equivalents has grown by 16.2% (from $402.47 million to $467.71 million).
- The most recent figure is from Immunocore Holdings plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: